Do analysts prefer ACON or AIFF?

Aclarion presently has a consensus target price of $7.50, suggesting a potential upside of 215.13%. Given Aclarion's stronger consensus rating and higher possible upside, research analysts plainly believe Aclarion is more favorable than Firefly Neuroscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclarion 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Firefly Neuroscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor ACON or AIFF?

In the previous week, Aclarion and Aclarion both had 3 articles in the media. Firefly Neuroscience's average media sentiment score of 0.14 beat Aclarion's score of 0.09 indicating that Firefly Neuroscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclarion 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Firefly Neuroscience 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend HCTI or ACON?

Aclarion has a consensus target price of $7.50, suggesting a potential upside of 215.13%. Given Aclarion's stronger consensus rating and higher probable upside, analysts clearly believe Aclarion is more favorable than Healthcare Triangle. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Healthcare Triangle 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aclarion 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor HCTI or ACON?

In the previous week, Healthcare Triangle and Healthcare Triangle both had 3 articles in the media. Aclarion's average media sentiment score of 0.09 beat Healthcare Triangle's score of 0.00 indicating that Aclarion is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Healthcare Triangle 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aclarion 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ITOC or ACON?

Aclarion has a consensus price target of $7.50, suggesting a potential upside of 215.13%. Given Aclarion's stronger consensus rating and higher possible upside, analysts plainly believe Aclarion is more favorable than Itonic. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Itonic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aclarion 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation and earnings, ITOC or ACON?

Itonic has higher revenue and earnings than Aclarion. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Itonic $520K 8.16 -$5.10M N/A N/A Aclarion $80K 85.68 -$7.23M -$7.40 N/A

Is ITOC or ACON more profitable?

Itonic has a net margin of 0.00% compared to Aclarion's net margin of -10,948.81%. Itonic's return on equity of 0.00% beat Aclarion's return on equity. Company Net Margins Return on Equity Return on Assets Itonic N/A N/A N/A Aclarion -10,948.81% -59.34% -56.12%

Does the media favor ITOC or ACON?

In the previous week, Itonic had 3 more articles in the media than Aclarion. MarketBeat recorded 6 mentions for Itonic and 3 mentions for Aclarion. Aclarion's average media sentiment score of 0.09 beat Itonic's score of -0.10 indicating that Aclarion is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Itonic 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aclarion 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer PTHL or ACON?

Aclarion has a consensus target price of $7.50, indicating a potential upside of 215.13%. Given Aclarion's stronger consensus rating and higher probable upside, analysts plainly believe Aclarion is more favorable than Pheton. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pheton 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aclarion 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings and valuation, PTHL or ACON?

Pheton has higher revenue and earnings than Aclarion. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pheton $305.22K 5.37 -$660K N/A N/A Aclarion $80K 85.68 -$7.23M -$7.40 N/A

Is PTHL or ACON more profitable?

Pheton has a net margin of 0.00% compared to Aclarion's net margin of -10,948.81%. Pheton's return on equity of 0.00% beat Aclarion's return on equity. Company Net Margins Return on Equity Return on Assets Pheton N/A N/A N/A Aclarion -10,948.81% -59.34% -56.12%

Do analysts recommend ACON or VSEE?

Aclarion presently has a consensus target price of $7.50, indicating a potential upside of 215.13%. Given Aclarion's stronger consensus rating and higher probable upside, equities analysts plainly believe Aclarion is more favorable than VSee Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aclarion 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 VSee Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ACON or VSEE more profitable?

VSee Health has a net margin of -92.36% compared to Aclarion's net margin of -10,948.81%. Aclarion's return on equity of -59.34% beat VSee Health's return on equity. Company Net Margins Return on Equity Return on Assets Aclarion -10,948.81% -59.34% -56.12% VSee Health -92.36% -11,636.34% -68.62%

Aclarion (ACON) Competitors

$2.38 -0.06 (-2.46%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$2.37 -0.01 (-0.34%)

As of 10/2/2026 07:55 PM Eastern

Compare

ACON vs. AIFF, HCTI, ITOC, PTHL, and VSEE

Should you buy Aclarion stock or one of its competitors? Aclarion's main competitors and comparable companies include Firefly Neuroscience (AIFF), Healthcare Triangle (HCTI), Itonic (ITOC), Pheton (PTHL), and VSee Health (VSEE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does Aclarion compare to Firefly Neuroscience?

Aclarion (NASDAQ:ACON) and Firefly Neuroscience (NASDAQ:AIFF) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

Firefly Neuroscience has a net margin of -506.23% compared to Aclarion's net margin of -10,948.81%. Aclarion's return on equity of -59.34% beat Firefly Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,948.81%	-59.34%	-56.12%
Firefly Neuroscience	-506.23%	-90.17%	-72.05%

Aclarion has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, Firefly Neuroscience has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market.

Aclarion has higher earnings, but lower revenue than Firefly Neuroscience. Firefly Neuroscience is trading at a lower price-to-earnings ratio than Aclarion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$80K	85.68	-$7.23M	-$7.40	N/A
Firefly Neuroscience	$1.14M	18.72	-$19.88M	-$0.59	N/A

Aclarion presently has a consensus target price of $7.50, suggesting a potential upside of 215.13%. Given Aclarion's stronger consensus rating and higher possible upside, research analysts plainly believe Aclarion is more favorable than Firefly Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Firefly Neuroscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Aclarion and Aclarion both had 3 articles in the media. Firefly Neuroscience's average media sentiment score of 0.14 beat Aclarion's score of 0.09 indicating that Firefly Neuroscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclarion	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Firefly Neuroscience	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

7.5% of Aclarion shares are held by institutional investors. Comparatively, 5.0% of Firefly Neuroscience shares are held by institutional investors. 0.0% of Aclarion shares are held by insiders. Comparatively, 6.9% of Firefly Neuroscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Aclarion beats Firefly Neuroscience on 10 of the 15 factors compared between the two stocks.

How does Aclarion compare to Healthcare Triangle?

Healthcare Triangle (NASDAQ:HCTI) and Aclarion (NASDAQ:ACON) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

In the previous week, Healthcare Triangle and Healthcare Triangle both had 3 articles in the media. Aclarion's average media sentiment score of 0.09 beat Healthcare Triangle's score of 0.00 indicating that Aclarion is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Healthcare Triangle	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aclarion	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

0.3% of Healthcare Triangle shares are owned by institutional investors. Comparatively, 7.5% of Aclarion shares are owned by institutional investors. 0.1% of Healthcare Triangle shares are owned by insiders. Comparatively, 0.0% of Aclarion shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Healthcare Triangle has a net margin of -66.85% compared to Aclarion's net margin of -10,948.81%. Aclarion's return on equity of -59.34% beat Healthcare Triangle's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Healthcare Triangle	-66.85%	-125.45%	-36.06%
Aclarion	-10,948.81%	-59.34%	-56.12%

Aclarion has a consensus target price of $7.50, suggesting a potential upside of 215.13%. Given Aclarion's stronger consensus rating and higher probable upside, analysts clearly believe Aclarion is more favorable than Healthcare Triangle.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Healthcare Triangle	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aclarion	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Healthcare Triangle has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market. Comparatively, Aclarion has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

Aclarion has lower revenue, but higher earnings than Healthcare Triangle. Aclarion is trading at a lower price-to-earnings ratio than Healthcare Triangle, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Healthcare Triangle	$13.89M	0.78	-$9.48M	-$33.52	N/A
Aclarion	$80K	85.68	-$7.23M	-$7.40	N/A

Summary

Aclarion beats Healthcare Triangle on 10 of the 15 factors compared between the two stocks.

How does Aclarion compare to Itonic?

Itonic (NASDAQ:ITOC) and Aclarion (NASDAQ:ACON) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

In the previous week, Itonic had 3 more articles in the media than Aclarion. MarketBeat recorded 6 mentions for Itonic and 3 mentions for Aclarion. Aclarion's average media sentiment score of 0.09 beat Itonic's score of -0.10 indicating that Aclarion is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Itonic	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aclarion	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aclarion has a consensus price target of $7.50, suggesting a potential upside of 215.13%. Given Aclarion's stronger consensus rating and higher possible upside, analysts plainly believe Aclarion is more favorable than Itonic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Itonic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aclarion	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Itonic has higher revenue and earnings than Aclarion.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Itonic	$520K	8.16	-$5.10M	N/A	N/A
Aclarion	$80K	85.68	-$7.23M	-$7.40	N/A

7.5% of Aclarion shares are held by institutional investors. 0.0% of Aclarion shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Itonic has a net margin of 0.00% compared to Aclarion's net margin of -10,948.81%. Itonic's return on equity of 0.00% beat Aclarion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Itonic	N/A	N/A	N/A
Aclarion	-10,948.81%	-59.34%	-56.12%

Itonic has a beta of 2.83, suggesting that its stock price is 183% more volatile than the broader market. Comparatively, Aclarion has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

Summary

Itonic and Aclarion tied by winning 7 of the 14 factors compared between the two stocks.

How does Aclarion compare to Pheton?

Pheton (NASDAQ:PTHL) and Aclarion (NASDAQ:ACON) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

Pheton has a beta of 5.4, indicating that its stock price is 440% more volatile than the broader market. Comparatively, Aclarion has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

Pheton has higher revenue and earnings than Aclarion.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pheton	$305.22K	5.37	-$660K	N/A	N/A
Aclarion	$80K	85.68	-$7.23M	-$7.40	N/A

7.5% of Aclarion shares are owned by institutional investors. 0.0% of Aclarion shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Aclarion had 3 more articles in the media than Pheton. MarketBeat recorded 3 mentions for Aclarion and 0 mentions for Pheton. Aclarion's average media sentiment score of 0.09 beat Pheton's score of 0.00 indicating that Aclarion is being referred to more favorably in the news media.

Company	Overall Sentiment
Pheton	Neutral
Aclarion	Neutral

Aclarion has a consensus target price of $7.50, indicating a potential upside of 215.13%. Given Aclarion's stronger consensus rating and higher probable upside, analysts plainly believe Aclarion is more favorable than Pheton.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pheton	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aclarion	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Pheton has a net margin of 0.00% compared to Aclarion's net margin of -10,948.81%. Pheton's return on equity of 0.00% beat Aclarion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pheton	N/A	N/A	N/A
Aclarion	-10,948.81%	-59.34%	-56.12%

Summary

Aclarion beats Pheton on 8 of the 14 factors compared between the two stocks.

How does Aclarion compare to VSee Health?

Aclarion (NASDAQ:ACON) and VSee Health (NASDAQ:VSEE) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment.

7.5% of Aclarion shares are owned by institutional investors. Comparatively, 1.0% of VSee Health shares are owned by institutional investors. 0.0% of Aclarion shares are owned by company insiders. Comparatively, 14.9% of VSee Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Aclarion presently has a consensus target price of $7.50, indicating a potential upside of 215.13%. Given Aclarion's stronger consensus rating and higher probable upside, equities analysts plainly believe Aclarion is more favorable than VSee Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
VSee Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Aclarion had 3 more articles in the media than VSee Health. MarketBeat recorded 3 mentions for Aclarion and 0 mentions for VSee Health. VSee Health's average media sentiment score of 0.37 beat Aclarion's score of 0.09 indicating that VSee Health is being referred to more favorably in the news media.

Company	Overall Sentiment
Aclarion	Neutral
VSee Health	Neutral

Aclarion has higher earnings, but lower revenue than VSee Health. VSee Health is trading at a lower price-to-earnings ratio than Aclarion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$80K	85.68	-$7.23M	-$7.40	N/A
VSee Health	$14.46M	0.49	-$14.71M	-$0.37	N/A

VSee Health has a net margin of -92.36% compared to Aclarion's net margin of -10,948.81%. Aclarion's return on equity of -59.34% beat VSee Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,948.81%	-59.34%	-56.12%
VSee Health	-92.36%	-11,636.34%	-68.62%

Summary

Aclarion beats VSee Health on 10 of the 15 factors compared between the two stocks.

Get Aclarion News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACON vs. The Competition

Export

Metric	Aclarion	Healthcare Technology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.86M	$1.74B	$7.16B	$13.28B
Dividend Yield	N/A	3.97%	2.53%	17.33%
P/E Ratio	-0.32	20.33	274.69	26.04
Price / Sales	85.68	87.60	610.13	91.98
Price / Cash	N/A	31.81	27.22	34.69
Price / Book	0.16	6.17	10.97	6.34
Net Income	-$7.23M	-$18.66M	$3.50B	$381.73M
7 Day Performance	-8.11%	-2.24%	-2.00%	-1.66%
1 Month Performance	1.28%	-1.21%	-6.19%	-4.68%
1 Year Performance	-67.82%	-21.68%	8.03%	1.57%

Aclarion Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACON Aclarion	2.845 of 5 stars	$2.38 -2.5%	$7.50 +215.1%	-67.8%	$6.86M	$80K	N/A	11	News Coverage Gap Up
AIFF Firefly Neuroscience	0.3534 of 5 stars	$1.20 -2.4%	N/A	-53.9%	$19.30M	$1.14M	N/A	17
HCTI Healthcare Triangle	0.4517 of 5 stars	$0.86 +10.8%	N/A	-99.5%	$11.68M	$13.89M	N/A	58	Gap Up
ITOC Itonic	1.0149 of 5 stars	$0.32 -2.9%	N/A	N/A	$5.63M	$520K	N/A	7	Earnings Report Short Interest Decrease Gap Down
PTHL Pheton	N/A	$0.33 +3.3%	N/A	-68.4%	$2.17M	$305.22K	N/A	11	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACON) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aclarion (ACON) Competitors

ACON vs. AIFF, HCTI, ITOC, PTHL, and VSEE

How does Aclarion compare to Firefly Neuroscience?

Summary

How does Aclarion compare to Healthcare Triangle?

Summary

How does Aclarion compare to Itonic?

Summary

How does Aclarion compare to Pheton?

Summary

How does Aclarion compare to VSee Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACON vs. The Competition

Aclarion Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aclarion (ACON) Competitors

ACON vs. AIFF, HCTI, ITOC, PTHL, and VSEE

How does Aclarion compare to Firefly Neuroscience?

Is ACON or AIFF more profitable?

Which has more volatility and risk, ACON or AIFF?

Which has better valuation and earnings, ACON or AIFF?

Do analysts prefer ACON or AIFF?

Does the media favor ACON or AIFF?

Do insiders and institutionals hold more shares of ACON or AIFF?

Summary

How does Aclarion compare to Healthcare Triangle?

Does the media favor HCTI or ACON?

Do institutionals and insiders hold more shares of HCTI or ACON?

Is HCTI or ACON more profitable?

Do analysts recommend HCTI or ACON?

Which has more risk & volatility, HCTI or ACON?

Which has higher valuation and earnings, HCTI or ACON?

Summary

How does Aclarion compare to Itonic?

Does the media favor ITOC or ACON?

Do analysts recommend ITOC or ACON?

Which has better valuation and earnings, ITOC or ACON?

Do insiders & institutionals hold more shares of ITOC or ACON?

Is ITOC or ACON more profitable?

Which has more volatility & risk, ITOC or ACON?

Summary

How does Aclarion compare to Pheton?

Which has more risk and volatility, PTHL or ACON?

Which has preferable earnings and valuation, PTHL or ACON?

Do institutionals and insiders have more ownership in PTHL or ACON?

Does the media prefer PTHL or ACON?

Do analysts prefer PTHL or ACON?

Is PTHL or ACON more profitable?

Summary

How does Aclarion compare to VSee Health?

Do insiders and institutionals believe in ACON or VSEE?

Do analysts recommend ACON or VSEE?

Does the media favor ACON or VSEE?

Which has stronger earnings and valuation, ACON or VSEE?

Is ACON or VSEE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACON vs. The Competition

Aclarion Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools